Showing 411-420 of 7755 results for "".
Journal Club: Tapinarof Cream in Pediatric Patients
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-tapinarof-cream-in-pediatric-patients/32399/Practical Dermatology Editorial Board member Peter Lio, MD, speaks with Mona Shahriari, MD, about the Journal of Dermatology article "A phase 2, randomized, double-blind, vehicle-controlled trial of tapinarof cream in Japanese pediatric patients with atopic dermatitis," and the general importance ofJournal Club: Treating Itch and Lessons from the IL-4 and IL-13 Blockade
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-treating-itch-and-lessons-from-the-il-4-and-il-13-blockade/27025/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, chats with dermatologist Matthew Zirwas, MD, about how evaluations of itch can lead to treatment for atopic dermatitis, and his Journal of Drugs in Dermatology article "Unexpected Clinical Lessons Learned From IL-4 and IL-13 Blockade."Cutaneous Toxicities in Graft-versus-host Disease
https://practicaldermatology.com/conferences/masterclasses-in-dermatology-2025/cutaneous-toxicities-in-graft-versus-host-disease/33013/Meghan Heberton, MD, an assistant professor of dermatology at UT Southwestern Medical Center, talks about her presentation at Masterclasses in Dermatology on the latest updates on cutaneous toxicities in Graft-versus-host (GvHD) disease.First Medication for Severe Frostbite; Biosimilar to Humira with Interchangeability Status Approved; Two Late-Stage AD Candidates Advance
https://practicaldermatology.com/series/dermwire-tv/first-medication-for-severe-frostbite-biosimilar-to-humira-with-interchangeability-status-approved-two-late-stage-ad-candidates-advance/20267/In this episode of DermWireTV, the first medication to treat severe frostbite is approved by the FDA; the first high-concentration biosimilar to Humira with interchangeability status will soon be available in the US; and two companies with late-stage atopic dermatitis candidates provide key updates.Tips for Success with Fillers
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/tips-for-success-with-fillers/20149/Heidi Waldorf, MD offers tips for getting the best results possible with fillers. From how to evaluate what patients need to considering shapes and proportions, she offers hands-on advice to help achieve optimal outcomes. Plus, she discusses the importance of managing patient expectations.Choosing the Right Resurfacing Treatment
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/choosing-the-right-resurfacing-treatment/20141/Joel L. Cohen, MD discusses how he assesses the area around the mouth to determine the best resurfacing treatment option. From fine lines and etching around the mouth to issues with pigmentation and redness, he says there are many options from low-downtime treatments to full-field erbium treatments.DermWireTV: Cutera, Galderma Acne Treatments; Alma's TED; Diversity Initiatives
https://practicaldermatology.com/topics/practice-management/dermwiretv-cutera-galderma-acne-treatments-almas-ted-diversity-initiatives/20084/There are two new options for treating acne. Cutera introduces the AviClear acne device; Galderma launches Twyneo Cream. Joshua Zeichner, MD weighs in. Lady Dy, MD discusses Alma’s TED device, a non-invasive, non-traumatic option to address hair loss. New initiatives announced at or in conjunction wEmerging Vitiligo Therapies
https://practicaldermatology.com/conferences/maui-derm-2022/emerging-vitiligo-therapies/20047/It’s really an exciting time to be treating vitiligo, says John E. Harris, MD, PhD. He reviews Phase 2 and 3 clinical trials for ruxolitinib, a topical JAK inhibitor, and the hope that the FDA could soon approve it for the treatment of vitiligo. He also discusses other possible targeted treatments iDermWireTV: Arcutis Takes PASI HD; Galderma at Camp Wonder; Amgen Challenge; LaRoche-Posay Pride
https://practicaldermatology.com/topics/psoriasis/dermwiretv-arcutis-takes-pasi-hd-galderma-at-camp-wonder-amgen-challenge-laroche-posay-pride/19996/The PASI high discrimination or PASI-HD tool was developed by Arcutis Biotherapeutics in collaboration with a panel of psoriasis research experts. Led by Amgen, in partnership with the International Federation of Psoriasis Associations, the Understanding Psoriatic Disease Leveraging Insights for TreHair Care Trends You Need to Know
https://practicaldermatology.com/conferences/aad-summer-2021/hair-care-trends-you-need-to-know/19976/People are sharing more than their latest dance moves on TikTok. Many—with no background in science—are dispensing hair care advice, some of which could even be dangerous. Learn which trends you should know about in order to educate your patients about what really works versus what could do more har